Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial.
Francesco PassigliaLuisella RighiPaolo BironzoAngela ListìGiovanni FarineaEnrica CapellettoSilvia NovelloAlessandra MerliniGiorgio Vittorio ScagliottiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
This preliminary analysis highlighted the lack of antitumor activity for the combination of niraparib and dostarlimab in patients with PM and/or advanced NSCLC harboring BAP1 somatic mutations. A potential antitumor activity emerged for PM with germline BAP1 and/or BRCA2 somatic mutations along with a good tolerability profile.
Keyphrases
- phase ii
- open label
- clinical trial
- phase iii
- particulate matter
- air pollution
- small cell lung cancer
- placebo controlled
- double blind
- copy number
- heavy metals
- polycyclic aromatic hydrocarbons
- study protocol
- randomized controlled trial
- dna repair
- water soluble
- gene expression
- advanced non small cell lung cancer
- oxidative stress
- dna damage
- dna methylation
- brain metastases
- climate change
- epidermal growth factor receptor
- data analysis